Evestia Clinical and Atlantic Research Group Merge to Form Global CRO Powerhouse

In a significant move that reshapes the contract research organization (CRO) landscape, Evestia Clinical and Atlantic Research Group have announced their merger to create a formidable global CRO. The newly formed entity, which will retain the Evestia Clinical name, aims to leverage the combined expertise of both companies in oncology, immunology, neurology, and late-stage clinical trials.

Merger Details and Strategic Vision

The merger, announced on July 15, 2025, brings together two CROs from opposite sides of the Atlantic Ocean. While the financial terms of the deal remain undisclosed, the strategic implications are clear. The combined company will double in size, establishing dual headquarters in Letchworth, UK, and Charlottesville, Virginia, USA.

Lyle Camblos, President of Atlantic Research Group, and Paul Bishop, CEO, expressed their enthusiasm for the merger, stating, "The highly experienced and globally recognized leadership team at Evestia Clinical is building a world-class specialist CRO provider and we are excited to bring across our whole team on this journey." They added, "We are pleased that our customers will be able to benefit from this seamless continuity as well as the combined group's enhanced capabilities."

Industry Trend: CRO Consolidation

This merger is not an isolated event in the CRO sector. It follows a recent trend of consolidation within the industry, as evidenced by the earlier merger between Julius Clinical and Peachtree BioResearch Solutions. That union, which occurred after nearly a decade of collaboration, resulted in Peachtree being branded as "a Julius Clinical company," with a primary focus on central nervous system diseases.

The Evestia-Atlantic merger and the Julius-Peachtree consolidation underscore a growing trend in the pharmaceutical services industry towards creating larger, more comprehensive CROs capable of offering a wider range of services and expertise to clients worldwide.